September 6th 2024
The FDA approved Boruzu, a new presentation of bortezomib, for subcutaneous or intravenous administration in patients with multiple myeloma and mantle cell lymphoma.
Trial Induces 'Best Ever' Survival Data Among Young Patients with Certain T-Cell Cancers
July 10th 2018Adding nelarabine to escalating-dose methotrexate increased the 4-year disease-free survival rate to 91% in pediatric and young adult patients with newly diagnosed T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma, according to results from the phase III AALL0434 trial.
Telephone Intervention Reduces Unplanned Hospitalizations for Patients With Blood Cancers
April 30th 2015A navigator-designed, proactive, weekly, telephone support call to help patients with blood cancers manage their symptoms between appointments was able to significantly reduce unplanned hospitalizations at a Colorado cancer center.